Archangels invests £2 million in 1nhaler
Thanks to Archangels, we are one step closer to bringing the world’s smallest, simplest, most sustainable single-dose inhaler to market. And we couldn’t be more delighted to be working with Sarah and the Archangels team.
“Don, Lisa and the team at 1nhaler have developed a truly innovative technology platform with a clear route to market and opportunity to positively disrupt the status quo of single-dose medicine delivery.
“We’re proud to add 1nhaler to our portfolio of Scotland’s leading life sciences and technology businesses and look forward to working with them to increase the availability of life-saving drugs affordably and sustainably.”
Dr Sarah Hardy, Director and Head of New Investments at Archangels